- for aerobic Gm Neg bact and Enteric &
P. aeruginosa
- Adult: 1-2gm IV/IM q6-12hr;
- Not effective for Gm pos nor anaerobic bacteria;
- Poor activity with:
Staph,
enterococci, NonEnteroStrep;
- may be given to Penicillin sensative individuals;
- Good diffusion from blood into CSF only with inflammation;
Ratio of CSF to Blood Level (%): Normal Meninges: 1;
Inflammed Meninges: 8-40;
- Dosing Regimens for Patients w/ Renal Insufficiency: (Dose for 70kg Adult
{gm/dosinginterval inhours}): CrCl:>80: 1-2/6; CrCl:50-79: 1-2/6;
CrCl:30-49: 1-2/6; CrCl:10-29: 0.5-1/6;;
- Note: this is a relatively safe drug, even in patients with impaired
renal function; Consequently because of the minimal risk of
nephrotoxicity with aztreonam, may clinicians advocate its use over
that of an aminoglycoside for the treatment of gram negative
infections in patients with renal insufficiency;
- Aztreonam is primary eliminated by the kidneys via tubular secretion
and GFR;
- in patients with end stage renal disease the drug may be administered
once daily;
- it is significantly removed by hemodialysis, therefore maintenence
doses should be administered after dialysis on dialysis days;
- Note: visual disturbances; Paresthesia: Convulsions;
--------------------------------------------
